Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Moderna partners with gene-editing company Metagenomi

by Ryan Cross
November 6, 2021 | A version of this story appeared in Volume 99, Issue 41

 

Moderna, known for its messenger RNA (mRNA) vaccines for COVID-19, is branching out into gene editing. Moderna has struck a research collaboration with Metagenomi, a start-up focused on discovering new enzymes for CRISPR gene editing and other gene-editing systems. The companies will encode the systems in mRNA molecules and package the molecules in Moderna’s lipid nanoparticles to treat genetic diseases. Metagenomi will get an undisclosed payment and investment from Moderna.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.